Achaogen

Developing novel antibacterials for Gram negative infections

Achaogen (NASDAQ: AKAO) is a clinical stage company focused on the discovery and development of novel antibiotics for multi-drug resistant (MDR) Gram negative bacteria. The company's lead asset, plazomicin, is in late-stage development to treat MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae that have been classified as an "urgent threat" by the CDC. Achaogen completed its IPO in 2014.

Status

IPO in 2014 (NASDAQ: AKAO)

Year of Investment

2011

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

South San Francisco, California

Website

Social Media